Tandem Diabetes Care Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care or view top-rated stocks.

Wall Street analysts have given Tandem Diabetes Care a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tandem Diabetes Care wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Tandem Diabetes Care.

Tandem Diabetes Care will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its earnings results on Wednesday, May, 5th. The medical device company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.08. The medical device company earned $141.04 million during the quarter, compared to the consensus estimate of $122.66 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 1.12% and a negative net margin of 4.53%.
View Tandem Diabetes Care's earnings history.

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TNDM stock has increased by 57.5% and is now trading at $104.44.
View which stocks have been most impacted by COVID-19.

Tandem Diabetes Care shares reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $625 million-$640 million, compared to the consensus revenue estimate of $610.52 million.

9 equities research analysts have issued 1 year price targets for Tandem Diabetes Care's shares. Their forecasts range from $90.00 to $150.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $123.11 in the next year. This suggests a possible upside of 17.9% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care or view top-rated stocks among Wall Street analysts.

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

Some companies that are related to Tandem Diabetes Care include NovoCure (NVCR), Teleflex (TFX), Insulet (PODD), Abiomed (ABMD), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), ShockWave Medical (SWAV), Integra LifeSciences (IART), Nevro (NVRO), Inspire Medical Systems (INSP), Inari Medical (NARI), ICU Medical (ICUI), AtriCure (ATRC) and Merit Medical Systems (MMSI).
View all of TNDM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Tandem Diabetes Care's stock is owned by many different retail and institutional investors. Top institutional investors include Compagnie Lombard Odier SCmA (0.00%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, James Leal, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, James Leal, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care or view top insider-selling stocks.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TNDM stock can currently be purchased for approximately $104.44.

Tandem Diabetes Care has a market capitalization of $6.54 billion and generates $498.83 million in revenue each year. The medical device company earns $-34,380,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

Tandem Diabetes Care employs 1,500 workers across the globe.

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Tandem Diabetes Care is headquartered at 11075 ROSELLE STREET, San Diego CA, 92121.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at (858) 366-6900 or via email at [email protected]